The present study also highlights Sirt3 as a candidate therapeutic target for antioxidant and mitochondria-protective agents that counteract the deleterious effects of Ang II on insulin sensitivity and paves the way for testing novel treatments for insulin resistance, metabolic syndrome, and possibly diabetes, based on the pharmacological modulation of Sirt3. This evidence concerns the gene SIRT3 and diabetes mellitus.